Compare CRSP & SRAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | SRAD |
|---|---|---|
| Founded | 2013 | 2001 |
| Country | Switzerland | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 5.0B |
| IPO Year | 2016 | 2021 |
| Metric | CRSP | SRAD |
|---|---|---|
| Price | $46.38 | $19.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 17 |
| Target Price | ★ $70.29 | $30.18 |
| AVG Volume (30 Days) | 2.0M | ★ 2.3M |
| Earning Date | 05-05-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,590,000.00 | N/A |
| Revenue This Year | $1,082.59 | $24.03 |
| Revenue Next Year | $87.74 | $15.00 |
| P/E Ratio | ★ N/A | $49.48 |
| Revenue Growth | ★ 9169.85 | N/A |
| 52 Week Low | $30.06 | $15.73 |
| 52 Week High | $78.48 | $32.22 |
| Indicator | CRSP | SRAD |
|---|---|---|
| Relative Strength Index (RSI) | 38.40 | 55.16 |
| Support Level | N/A | $17.68 |
| Resistance Level | $60.63 | $19.67 |
| Average True Range (ATR) | 2.30 | 0.89 |
| MACD | -0.84 | 0.14 |
| Stochastic Oscillator | 10.22 | 60.82 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.